TARGETING IMPROVED TREG SELECTIVITY WITH THE IL-2 MUTEIN EFAVALEUKIN ALFA: RATIONALE FOR IL-2 THERAPY IN ULCERATIVE COLITIS
Farshid Firoozbakht 1
Nandita Sarkar 2
Kevin Gorski 2
Nadia Tchao 2
1 Amgen Inc., Thousand Oaks, United States
2 Amgen Inc., South San Francisco, United States
Topic
IBD
Session
PP 05 IBD (Posters)
Conference
UEG Week 2023
Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]